Tamara Gurevich, MD
Physical Medicine & Rehabilitation · Buffalo Grove, ILNPI 1336227503
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 50.0% of the total. Among physical medicine & rehabilitation clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$640
- IBSA Pharma Inc.$337
- E.r. Squibb & Sons, L.L.C.$214
- Johnson & Johnson$148
- Abbott$110
- plus $711 from 22 others
What the payments were for
- Food & beverage$4,317100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 128 | $2,163 |
| Amgen(2 entities) | 23 | $640 |
| IBSA Pharma Inc. | 18 | $337 |
| E.r. Squibb & Sons, L.L.C. | 11 | $214 |
| Johnson & Johnson(2 entities) | 8 | $148 |
| Abbott | 6 | $110 |
| Biotronik NRO, Inc. | 2 | $103 |
| UCB, Inc. | 4 | $89 |
| Fidia Pharma USA Inc. | 3 | $53 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| Biodelivery Sciences International, Inc. | 3 | $38 |
| AstraZeneca | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Pfizer | 1 | $26 |
| Sanofi | 1 | $25 |
| Si-bone, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Orthogenrx Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Relievant Medsystems, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Bioventus LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$102
How this compares
$4,324 in reported general payments places this provider in the 95th percentile of 433 physical medicine & rehabilitation providers in Illinois.
See all physical medicine & rehabilitation providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 18 | $125,728 |
| EnbrelEtanercept | 11 | $84,562 |
| UbrelvyUbrogepant | 13 | $14,868 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 314 | $8,535 |
| Diclofenac Sodium | 52 | $2,514 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $2,193 |
| Lidocaine | 15 | $2,037 |
| Gabapentin | 60 | $1,468 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $712 |
| Ventolin HfaAlbuterol Sulfate | 12 | $670 |
| Celecoxib | 17 | $531 |
| Nebivolol Hcl | 14 | $497 |
| Hydroxychloroquine Sulfate | 24 | $384 |
| Tramadol Hcl | 66 | $328 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 13 | $261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Ubrelvy | $2,163 | $140,59631 claims |
| AmgenEnbrel | $640 | $84,56211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 433 physical medicine & rehabilitation providers in Illinois.
Other physical medicine & rehabilitation in Buffalo Grove
- Zachary McCormickChicago$290K
- Shivani GuptaOak Lawn$201K
- David SchneiderBarrington$30K
- Hugh McDermottMaywood$22K
- Prasanth KattaSycamore$19K
- Ravi KasiChicago$17K
- Steven KreisChicago$16K
- Henry GuanChicago$11K
- Ibrahim Usman-OyoweChicago$10K
- David RosaniaHinsdale$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.